Neutrophil/Lymphocyte (N/L) Ratio and Long Term Follow-up in ST-elevation Myocardial Infarction

NCT01663194 | Completed

• 1 other identifier: mgkaya-makpek
• Study Type: observational
• Target: 1,034
• Locations: 1 country
• Sites: 1

Brief Summary

Although the pre-procedural neutrophil to lymphocyte ratio (N/L) has been associated with adverse outcomes among patients with coronary artery disease, its role during the acute phase of ST-segment elevation myocardial infarction (STEMI) has not been fully investigated. This study sought to investigate the association of the pre-procedural N/L ratio within-hospital and long-term outcomes among STEMI patients undergoing primary percutaneous coronary intervention (PCI).

Conditions

ST Elevated Myocardial Infarction

Keywords

N/L ratio, STEMI, primary PCI, Long-term mortality

Study Arms (3)

N/L ratio tertile 2

patients were divided in to the tertiles

Procedure: primary percutaneous coronary intervention, each groups

N/L ratio tertile 3

patients were divided in to the tertiles

Procedure: primary percutaneous coronary intervention, each groups

N/L ratio tertile 1

patients were divided in to the tertiles

Procedure: primary percutaneous coronary intervention, each groups

Interventions

primary percutaneous coronary intervention, each groups PROCEDURE

All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).

N/L ratio tertile 1; N/L ratio tertile 2; N/L ratio tertile 3

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

STEMI patients who were admitted within 6 hours from symptom onset and who underwent primary PCI were prospectively included in this study

You may qualify if:

• ST elevated myocardial infarction

You may not qualify if:

• Treatment with fibrinolytic drugs in the previous 24 hours Active infection Previously documented history of a systemic inflammatory process Known malignancy End-stage liver disease Renal failure

Sponsors & Collaborators

• TC Erciyes University: lead

Study Sites (1)

Erciyes University school of medicine

Kayseri, 38039, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum and plasma of blood

MeSH Terms

Conditions

ST Elevation Myocardial Infarction

Condition Hierarchy (Ancestors)

Myocardial Infarction; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis

Study Officials

• Mahmut Akpek, MD

  Erciyes University school of medicine

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical doctor of cardiology department

Study Record Dates

• First Submitted: August 9, 2012
• First Posted: August 13, 2012
• Study Start: January 1, 2000
• Primary Completion: July 1, 2012
• Study Completion: July 1, 2012
• Last Updated: August 14, 2012

Record last verified: 2012-08

Locations

TU (1)